Pfizer faces another securities fraud suit over Bextra marketing
This article was originally published in Scrip
Executive Summary
Pfizer faces another securities fraud class action over the marketing of its COX-2 inhibitor Bextra (valdecoxib), with the plaintiffs alleging the company failed to inform investors that it was illegally promoting off-label uses of Bextra and improperly marketing three other products.